INTICA Biomedical, Inc.
Precision Medicine: Novel Therapeutic & Companion Diagnostic for Triple Negative Breast Cancer (NCI - Contract & Grant Recipient)
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.